| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.36.6.777 |
| P698 | PubMed publication ID | 3486383 |
| P50 | author | David A. Hafler | Q25004567 |
| P2093 | author name string | Weiner HL | |
| Reinherz EL | |||
| Schlossman SF | |||
| Fallis RJ | |||
| Dawson DM | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| antibody | Q79460 | ||
| P304 | page(s) | 777-784 | |
| P577 | publication date | 1986-06-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. | |
| P478 | volume | 36 |
| Q37390483 | A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis |
| Q40770881 | Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells |
| Q58874863 | Antibodies in Phase III Studies for Immunological Disorders |
| Q41476987 | CD318 is a ligand for CD6. |
| Q42177117 | CD6 as a potential target for treating multiple sclerosis |
| Q34337963 | CD6 as a therapeutic target in autoimmune diseases: successes and challenges. |
| Q35818957 | CD6 attenuates early and late signaling events, setting thresholds for T-cell activation |
| Q38341487 | CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction |
| Q67903116 | Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway |
| Q36577212 | Drug insight: using monoclonal antibodies to treat multiple sclerosis |
| Q37165875 | Getting specific: monoclonal antibodies in multiple sclerosis. |
| Q33573621 | Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab |
| Q37138277 | Immunological evaluation of rheumatoid arthritis patients treated with itolizumab |
| Q39644393 | Immunotherapy of multiple sclerosis |
| Q47600178 | Influence of antioxidant enzymes in reduction of optic disc edema in experimental optic neuritis |
| Q24656799 | Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci |
| Q41663237 | Passage of intravenous immunoglobulin and interaction with the CNS. |
| Q61651685 | Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis |
| Q68110853 | Quantitation of human anti-mouse antibody in serum by flow cytometry |
| Q38730494 | Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases |
| Q39695604 | T cells in multiple sclerosis and inflammatory central nervous system diseases |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q24336427 | The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins |
| Q52724558 | The role of CD6 in autoimmune diseases. |
| Q41563302 | The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications |
| Q40518542 | Therapy for multiple sclerosis. |
Search more.